Contradicting preliminary results are available on the impact of COVID-19 in people with HIV (PWH). How achieving goals of the HIV 90-90-90 cascade of care influences the risk of COVID-19 in PWH is unclear. The primary objective is to determine the impact of COVID-19 in PWH cohorts from Ukraine and the Netherlands.
Study Type
OBSERVATIONAL
Enrollment
1,100
Erasmus MC
Rotterdam, Netherlands
Lviv Regional AIDS Health Center
Lviv, Ukraine
Prevalence COVID19
Prevalence (percent) of clinical COVID-19 in PWH cohorts from Ukraine and in the Netherlands.
Time frame: Up to 2 years
Incidence COVID-19
Incidence (nr cases/person years) of clinical COVID-19 cases in PWH cohorts from Ukraine and in the Netherlands
Time frame: Up to 2 years
WHO categories COVID-19
Prevalence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands.
Time frame: Up to 2 years
WHO categories COVID-19
Incidence of no suspicion, possible, probable and proven COVID-19 cases in the past 6 months PWH cohorts from Ukraine and the Netherlands.
Time frame: Up to 2 years
WHO disease severity COVID-19
Proportion of COVID-19 patients according to the severity of COVID-19 on an adapted World Health Organisation 5 point disease severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in people with HIV cohorts from Ukraine and the Netherlands.
Time frame: Up to 2 years
Seroprevalence
Anti-SARSCOV2 seroprevalence in PWH cohorts from Ukraine and the Netherlands
Time frame: Up to 2 years
NPV/PPV WHO categories COVID19
Positive and negative predictive value of the WHO COVID-19 case probability categories on anti-SARSCOV2 serology in PWH cohort from Ukraine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 2 years
Treatment
Description of COVID-19 therapeutic management in PWH cohorts from Ukraine and the Netherlands
Time frame: Up to 2 years
Predictors for COVID-19
Predictor variables for having clinical COVID-19 in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (\<50, 50-70, \>70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (\<=50 / \>50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs \>1).
Time frame: Up to 2 years
Predictors for COVID-19 severity
Predictor variables for the highest score on an ordinal scale for COVID-19 severity according to the adapted 5point WHO severity scale (where 1=no symptoms, 2=symptoms but outpatient, 3=admitted to hospital, 4=admitted to ICU, 5=fatal) in PWH cohorts from Ukraine and the Netherlands according to 1) sex, 2) age categories (\<50, 50-70, \>70), 3) ART (LPV/r vs other and TDF containing vs non-TDF containing regimens), 4) most recent CD4+T-cell 5) HIV-RNA suppressed (\<=50 / \>50), 6) prior TB, 7) prior BCG, 8) HIV transmission group, 9) comorbidities (0 vs 1 vs \>1)
Time frame: Up to 2 years